{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:54:12Z","timestamp":1765212852350,"version":"3.46.0"},"reference-count":27,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Neuromyelitis Optica Spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system with a globally heterogeneous prevalence\/ To estimate the prescription-based prevalence of NMOSD in Greece and determine the use of long-term immunotherapies and concomitant medications in these patients. Methods: We analyzed anonymized prescription records from the national prescription database, dating from 1 January 2017 to 1 May 2024. The administrative point prevalence of NMOSD in Greece on 1 January 2022 was calculated according to the national census conducted in late 2021. Results: We identified 219 cases of NMOSD and a 1:6.8 male-to-female ratio. The point prevalence on 1 January 2022 was 1.97 per 100,000, with the highest detected in the region of Crete, and the lowest in the regions of Eastern Macedonia and Thrace. The mean age of people with NMOSD on that date was 51.3 years old. Azathioprine was the most frequently prescribed maintenance immunotherapy, while antidepressants were the most common concomitant medications prescribed. Polypharmacy was observed in 28.9% of the identified cases. Conclusions: We hereby present the prescription drug use of people with NMOSD in Greece in the era just before the introduction of NMOSD-specific immunotherapy in Greece.<\/jats:p>","DOI":"10.3390\/jcm14248665","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8665","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription Drug Use in NMOSD: A Population-Based Study in Greece with Estimation of National Disease Administrative Prevalence"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-3707","authenticated-orcid":false,"given":"Christos","family":"Bakirtzis","sequence":"first","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2280-5444","authenticated-orcid":false,"given":"Natalia","family":"Konstantinidou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9529-5324","authenticated-orcid":false,"given":"Sotiria","family":"Stavropoulou De Lorenzo","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4258-1200","authenticated-orcid":false,"given":"Nikolaos","family":"Mitsoudis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-196X","authenticated-orcid":false,"given":"Theodoros","family":"Moysiadis","sequence":"additional","affiliation":[{"name":"Department of Computer Science, School of Sciences and Engineering, University of Nicosia, Nicosia 2417, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4300-2826","authenticated-orcid":false,"given":"Dimitrios","family":"Parisis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-5163","authenticated-orcid":false,"given":"Marina Kleopatra","family":"Boziki","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-9210","authenticated-orcid":false,"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-3301","authenticated-orcid":false,"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Ahepa University Hospital, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"Giglhuber","year":"2024","journal-title":"J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 Antibodies (NMO\u2013IGG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): A systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hor, J.Y., Asgari, N., Nakashima, I., Broadley, S.A., Leite, M.I., Kissani, N., Jacob, A., Marignier, R., Weinshenker, B.G., and Paul, F. (2020). Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00501"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: A review and meta-analysis","volume":"71","author":"Arnett","year":"2024","journal-title":"J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/13524585231224683","article-title":"Prevalence of neuromyelitis optica spectrum disorder in the United States","volume":"30","author":"Briggs","year":"2024","journal-title":"Mult. Scler. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: A population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bakirtzis, C., Grigoriadou, E., Boziki, M.K., Kesidou, E., Siafis, S., Moysiadis, T., Tsakona, D., Thireos, E., Nikolaidis, I., and Pourzitaki, C. (2020). The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.01012"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103534","DOI":"10.1016\/j.msard.2022.103534","article-title":"Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany","volume":"59","author":"Holstiege","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/13524585241245318","article-title":"Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study","volume":"30","author":"Demir","year":"2024","journal-title":"Mult. Scler. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123110","DOI":"10.1016\/j.jns.2024.123110","article-title":"Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder","volume":"463","author":"Patel","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Masnoon, N., Shakib, S., Kalisch-Ellett, L., and Caughey, G.E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatr., 17.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/1352458516671203","article-title":"Influence of female sex and fertile age on neuromyelitis optica spectrum disorders","volume":"23","author":"Borisow","year":"2017","journal-title":"Mult. Scler. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/bs.irn.2022.06.011","article-title":"Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)","volume":"164","author":"Diem","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1212\/WNL.0000000000007746","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ene.14079","article-title":"A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary","volume":"27","author":"Papp","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primer."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102685","DOI":"10.1016\/j.msard.2020.102685","article-title":"Frequency of comorbidities in Neuromyelitis Optica spectrum disorder","volume":"48","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: Patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8665\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:50:03Z","timestamp":1765212603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":27,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248665"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248665","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}